Kyverna Therapeutics Stock Skyrockets 41%: CAR T-Cell Therapy Shows Promising Results in Rare Autoimmune Disease Treatment

Kyverna Therapeutics' stock rose 41% in a month following positive top-line data from a pivotal phase II study for its lead CAR T-cell therapy candidate, mivocabtagene autoleucel, in stiff person syndrome. The study met primary and secondary endpoints with high statistical significance, and the company plans to file a biologics license application in the first half of 2026. Kyverna is also evaluating the candidate in phase II/III registrational studies for generalized myasthenia gravis and has received Regenerative Medicine Advanced Therapy and Orphan Drug designations for SPS.